Omeros (OMER) Expected to Announce Earnings on Monday

Omeros (NASDAQ:OMER) is expected to be releasing its earnings data after the market closes on Monday, March 24th. Analysts expect Omeros to post earnings of ($0.69) per share for the quarter.

Omeros Price Performance

Omeros stock opened at $9.10 on Friday. The firm has a 50 day simple moving average of $8.70 and a 200-day simple moving average of $7.32. The stock has a market capitalization of $527.35 million, a PE ratio of -3.94 and a beta of 2.03. Omeros has a 12-month low of $2.61 and a 12-month high of $13.60.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Friday, January 17th. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Friday. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.